Form 4 for AURA Aura Biosciences, Inc.

Accepted 2025-02-04 00:00:00 ET · period of report 2025-02-03 · accession 0000950170-25-013830 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2025-02-04	2025-02-03	AURA	de los Pinos Elisabet	See Remarks, Dir	A - Grant	$0.00	+194.3K	502.7K	+63%	$0
D	2025-02-04	2025-02-03	AURA	de los Pinos Elisabet	See Remarks, Dir	A - Grant	$0.00	+255.7K	255.7K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-02-03	A	A	194,320	$0.00	502,661	D	—	—	(F1) These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on February 15, 2026, subject to the Reporting Person's continued service as of each such vesting date. (F2) On November 7, 2023, the Reporting Person filed a Form 4 which incorrectly included an additional 3,649 shares in the amount of securities beneficially owned directly after the reported transaction and excluded 3,649 shares from the amount of securities beneficially owned indirectly after the reported transaction. The Reporting Person's holdings after the transactions reported on this Form 4 reflect this correction.
2	Derivative	Stock Option (Right to Buy)	2025-02-03	A	A	255,680	$0.00	255,680	D	$7.68 · — to 2035-02-02	255,680 Common Stock	(F4) The shares underlying this option vest as follows: 25% of the shares vest on February 3, 2026 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.